Hemab Therapeutics has concluded an oversubscribed Series C funding round, raising $157m to further develop therapies for bleeding disorders.
The investment round was spearheaded by Sofinnova Partners and saw contributions from a global asset management company.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
New investors, along with a sovereign wealth fund and Avoro Capital Advisors, joined the round, with continued support from existing stakeholders Access Biotechnology, Avoro Ventures, Deep Track Capital, Invus, Maj Invest Equity, Novo Holdings, RA Capital Management and Rock Springs Capital.
As a result of this financial milestone, Sofinnova partner Joe Anderson will take a seat on the Hemab board.
Among the treatments that are being developed is sutacimig, a bispecific antibody designed for subcutaneous administration. It functions by binding and stabilising endogenous Factor VIIa.
Sutacimig, previously known as HMB-001, is poised to become the inaugural prophylactic therapy for Glanzmann thrombasthenia (GT), a severe bleeding disorder.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFollowing the completion of a Phase II trial of sutacimig for GT, Hemab is preparing to progress to a registration trial in 2026.
The company also plans to expand into a Phase II trial in Factor VII deficiency.
The funding will further facilitate the advancement of HMB-002, another treatment based on antibody, towards a registration trial.
A Phase I proof of mechanism data demonstrated that HMB-002 addresses the pathophysiology of Von Willebrand disease directly and increases levels of both Von Willebrand Factor and Factor VIII.
With the additional financial resources, the company aims to bring new drug candidates into clinical development, with the announcement of HMB-003 anticipated in the first half of 2026.
Hemab Therapeutics CEO Benny Sorensen stated: “The quality of our investor syndicate and this significant financing validate our approach and enable us to continue building what we believe will become the ultimate clotting company. We carefully listen to people living with clotting diseases and collaborate closely with patients and families affected by these conditions to deliver 21st century treatment options.
“Hemab’s unprecedented deep domain expertise in clotting science, combined with our team’s proven capabilities in advancing programmes from early development through approval and commercialisation, uniquely positions us to deliver breakthrough therapies.”
